Bryn Mawr Capital Management LLC Lowers Stock Position in Pfizer Inc. (NYSE:PFE)

Bryn Mawr Capital Management LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 17.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 69,820 shares of the biopharmaceutical company’s stock after selling 14,630 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Pfizer were worth $1,914,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the fourth quarter worth $26,000. Gladius Capital Management LP raised its holdings in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares during the period. Teachers Insurance & Annuity Association of America acquired a new position in Pfizer during the 3rd quarter worth about $35,000. Joseph Group Capital Management boosted its holdings in Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 771 shares during the period. Finally, Sierra Ocean LLC acquired a new position in Pfizer in the 4th quarter valued at about $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $25.86 on Friday. The company has a market capitalization of $146.52 billion, a price-to-earnings ratio of 18.34, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a 50 day moving average price of $26.28 and a 200 day moving average price of $27.44.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. Research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.65%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 121.99%.

Analyst Upgrades and Downgrades

PFE has been the topic of several research reports. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. UBS Group cut their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Finally, Guggenheim restated a “buy” rating and set a $33.00 price target on shares of Pfizer in a report on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.